Cytokinetics (CYTK) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $79.17 +0.50%
Revenue Growth %: -75.4%
Financial Fact:
Interest and other, net: 111K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -75.4%
Financial Fact:
Interest and other, net: 111K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($0.51), in-line with the analyst estimate of ($0.51). Revenue for the quarter came in at $6.22 million versus the consensus estimate of $5.19 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Hermès can regain momentum despite China weakness, Jefferies says
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
